Proleukin®

Interleukin 2 (Aldesleukin, Proleukin ) is a major growth factor and activator of cytotoxic and other T-lymphocytes. It is applied in the therapy of metastas-ing renal carcinoma and melanoma. Side effects include... [Pg.411]

Proleukin Aldesleukin (interleukin 2) Chiron Renal cell carcinoma, metastatic melanoma... [Pg.694]

Proleukin (IL-2) Lyophile for IV injection single-use vial 2-8°C reconstituted solution stable 48 hours at 2-8°C 1.1 mg vial 50mg mannitol, 0.18 mg Na.dodec.sulfate,1.6mg NaP04... [Pg.709]

The bacterium Escherichia coli is preferred for the production of small, aglycosy-lated proteins like Insulin, Proleukin (interleukin-2), Kineret (interleukin-1 recep-... [Pg.267]

Procrit , Epoietin alfa Proleukin, IL-2 Aldesleukin Ortho Biotech, Inc. Chiron... [Pg.147]

Proleukin, IL-2 Aldesleukin Rebetron ribavirin/IFN alfa-2b Chiron Schering-Plough Corp. [Pg.147]

Proleukin is a recombinant form of IL-2. It is approved for the treatment of malignant melanoma and renal cell cancer. Ontak (denileukin diftitox) is a fusion protein for the treatment of persistent or recurrent T-cell lymphoma. Activated T cells express lL-2 receptors. Ontak has a fragment that binds to the IL-2 receptor while the other part presents a diphtheria toxin to kill the activated T cell. [Pg.117]

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. [Pg.160]

Proleukin (rIL-2) Approved (1992) Renal cell carcinoma Chiron Corp. [Pg.224]

Proleukin (rIL-2, differs from human molecule in that it is devoid of an N-terminal alanine and Cys 125 has been replaced by a Ser. Produced in E. coli) Chiron Renal cell carcinoma 1992 (USA)... [Pg.503]

C. Interleukins aldesleukin (interleukin-2, IL-2, Proleukin) Cellular growth factors... [Pg.639]

IL-2 (Proleukin) is a cytokine that promotes the proliferation, differentiation, and recruitment of T and B lymphocytes, natural killer cells, and thymocytes. Human recombinant IL-2 is designated as rIL-2. rIL-2 binds to IL-2 receptors on responsive cells and induces proliferation and differentiation of T helper cells and T cytotoxic cells. It also can induce B-lymphocyte proliferation, activate macrophage activity, and augment the cytotoxicity of natural killer cells. [Pg.662]

B. Indications and nse Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma. Proleukin is also indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of the cytokine. [Pg.200]

Dosage form Proleukin is supplied as a sterile, lyophilized cake in single-use vials intended for injection on reconstitution with sterile water for injection. When reconstituted, each ml contains aldesleukin 18 million lU (1.1 mg). [Pg.200]

Ronte of administration Proleukin is given as an intravenous infusion over 15 minutes. [Pg.200]

Recommended dosage and monitoring requirements The dose of Proleukin in metastatic renal cell carcinoma is 600,000 units/kg every 8 hours for a maximum of 14 doses. Following 9 days of rest, the schedule is repeated for another 14... [Pg.200]

Drug interactions Proleukin may affect central nervous system function. Therefore interactions could occur following concomitant administration of psychotropic drugs. Concurrent administration of drugs possessing nephrotoxic, myelotoxic, cardiotoxic, or hepatotoxic effects with Proleukin may increase toxicity in these organ systems. Reduced kidney and liver function secondary to Proleukin treatment may delay elimination of concomitant medications and increase the risk of adverse events from those drugs. Beta-blockers and other antihypertensives may potentiate the hypotension seen with Proleukin. [Pg.201]

E. Therapeutic response In renal cell carcinoma studies, an objective response was seen in 15% of patients, with 7% complete and 8% partial responders. In metastatic melanoma studies, an objective response was seen in 16% of patients, with 6% complete and 10% partial responders. In patients with HIV infection, Proleukin increases the CD4 count, with no effect on viral load. [Pg.201]

G. Other applications Proleukin may also be useful in the management of HIV infection. [Pg.201]

H. Other considerations Proleukin has been designated an orphan drug for use in the treatment of metastatic renal cell carcinoma, metastatic melanoma, non-Hodgkin s lymphoma, and primary immunodeficiency disease associated with T-cell defects. [Pg.201]

Interferons and cytokines Aldesleukin, human recombinant interleukin-2, produced Proleukin Lyophilized, 22 X 10 lU vial, reconstitute and use within 48 h IM... [Pg.461]

Milan S, Wilson SE, Kahn KD et al. Investigation of FcgammaR polymorphisms and response to IL-2 (Proleukin ) and rituximab treatment in rituximab-resistant ISTHL patients importance of the F/F polymorphism at position 158 of the Fcgamma. Blood 2004 104 239b. [Pg.228]

See also in sourсe #XX -- [ Pg.246 ]

See also in sourсe #XX -- [ Pg.64 ]

See also in sourсe #XX -- [ Pg.224 , Pg.228 , Pg.503 ]

See also in sourсe #XX -- [ Pg.199 , Pg.200 ]

See also in sourсe #XX -- [ Pg.64 ]

See also in sourсe #XX -- [ Pg.36 ]

See also in sourсe #XX -- [ Pg.578 ]

See also in sourсe #XX -- [ Pg.84 , Pg.85 , Pg.86 , Pg.87 , Pg.88 , Pg.89 , Pg.90 , Pg.91 , Pg.92 , Pg.93 , Pg.94 ]

See also in sourсe #XX -- [ Pg.278 ]

See also in sourсe #XX -- [ Pg.64 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...